4basebio PLC has appointed a CEO to take over from the founder of the BioTech.

The firm, which accelerates development of advanced therapy medicinal products through synthetic DNA products, said Dr Amy Walker will succeed Dr Heikki Lanckriet.

Dr Lanckriet has stepped down to lead a newly formed entity which will be focused on advancing the Hermes nanoparticle platform into the clinic. David Roth will join him and step down as CFO and as a director at 4basebio, following an orderly handover period.

Dr Walker has been with the company for more than five years, most recently serving as COO.